AWM
ABBV icon

Abound Wealth Management’s AbbVie ABBV Stock Holding History

Abound Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$354K Sell
1,408
-284
-17% -$61.1K 0.07% 60
2026
Q1 		$368K Buy
1,692
+147
+10% +$32.6K 0.08% 60
2025
Q4 		$353K Buy
1,545
+7
+0.5% +$1.59K 0.08% 57
2025
Q3 		$356K Buy
1,538
+7
+0.5% +$1.43K 0.09% 54
2025
Q2 		$284K Buy
1,531
+4
+0.3% +$743 0.08% 56
2025
Q1 		$320K Buy
1,527
+136
+10% +$26.4K 0.11% 51
2024
Q4 		$247K Sell
1,391
-105
-7% -$19.3K 0.08% 59
2024
Q3 		$295K Hold
1,496
– – 0.1% 48
2024
Q2 		$257K Buy
1,496
+179
+14% +$29.7K 0.09% 48
2024
Q1 		$240K Sell
1,317
-197
-13% -$34K 0.09% 52
2023
Q4 		$235K Buy
1,514
+122
+9% +$17.8K 0.09% 50
2023
Q3 		$207K Hold
1,392
– – 0.09% 51
2023
Q2 		$188K Buy
1,392
+191
+16% +$28K 0.08% 55
2023
Q1 		$191K Buy
1,201
+145
+14% +$22.2K 0.09% 53
2022
Q4 		$171K Buy
1,056
+121
+13% +$18.6K 0.08% 53
2022
Q3 		$126K Buy
+935
New +$134K 0.07% 53

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Abound Wealth Management's ABBV Position: Q2 2026 in Review

Abound Wealth Management reduced its AbbVie (ABBV) stake by 17% in Q2 2026, selling an estimated $61.1K and leaving 1,408 shares worth $354K. The position accounts for 0.07% of the portfolio, ranked #60.

Abound Wealth Management first reported a position in ABBV in Q3 2022 and has held it in 16 quarters since. The position peaked at $368K in Q1 2026. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Abound Wealth Management held 1,408 shares of AbbVie worth $354K as of Q2 2026.
  • Abound Wealth Management sold 284 AbbVie shares in Q2 2026, an estimated $61.1K.
  • AbbVie made up 0.07% of Abound Wealth Management's portfolio in Q2 2026, its #60 holding.
  • Abound Wealth Management first reported a position in AbbVie in Q3 2022 and has held it in 16 quarters since.
  • Abound Wealth Management's AbbVie position peaked at $368K in Q1 2026.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.